Altor BioScience Corporation Announces FDA Fast Track Designation for Lead Candidate ALT-803 in Patients with Non-Muscle Invasive Bladder Cancer

Altor BioScience Corporation announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational interleukin-15 (IL-15) agonist complex, ALT-803, in combination with bacillus Calmette-Guérin (BCG), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). The FDA’s Fast Track program is designed to expedite the development and review of drugs to treat serious conditions and fill unmet medical needs.

 

Read More

NantHealth, NantKwest and NantOmics Announce Availability of GPS Cancer and Phase I-III QUILT Trials Through the U.S. National Institute of Health's ClinicalTrials.gov

NantHealth, Inc., a leading next-generation, evidence-based, personalized healthcare company, together with NantKwest and NantOmics, today announced the public availability of QUILT Programs (Quantum Immuno-oncology Lifelong Trial), aimed to harness and orchestrate all elements of the immune system through the testing of novel treatment combinations, within the national clinical trials database, www.ClinicalTrials.gov

Read More

Medical breakthroughs enhance health, economy of region

Medical breakthroughs enhance health, economy of region

The recent groundbreaking ceremony in Richland Township paves a way for the establishment of the Johnstown Heart and Vascular Center in the region. The collaboration with Windber hospital represents the positive impact of the medical center on the community that would now have access to basic as well as comprehensive cardiovascular care in the growing Richland region. In the future, the Windber hospital will hold clinical trials for cancer treatment, and will further connect the research institute’s science with other Cancer Breakthroughs 2020 efforts across the globe to improve treatments and eventually eradicate cancer.

 

Read More

Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapeutics, announced enrollment is complete for the first cohort in a Phase 1b/2 trial using ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, in combination with the approved anti-PD-1 antibody (Ab) nivolumab (Opdivo®; Bristol-Myers Squibb) for patients with pre-treated, advanced, or metastatic non-small cell lung cancer (NSCLC). This Investigator-Sponsored Trial is being conducted under the direction of John Wrangle, M.D., M.P.H., at the Medical University of South Carolina (MUSC).

Read More